Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DY13WU
|
|||
| Drug Name |
TAS-0728
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
Taiho Oncology
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03410927) A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities. U.S. National Institutes of Health. | |||
| REF 2 | TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2019 Apr;18(4):733-742. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.